Compumedics (ASX:CMP) LT-Debt-to-Total-Asset: 0.01 (As of Dec. 2025)

What is Compumedics LT-Debt-to-Total-Asset?

Compumedics ASX:CMP +2.00% 61 LT-Debt-to-Total-Asset is 0.01 as of Dec. 2025. GuruFocus rates ASX:CMP with a GF Score™ of 61/100 and a GF Value™ of A$0.31 (Modestly Undervalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Compumedics's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.01.

Compumedics's long-term debt to total assets ratio increased from Dec. 2024 (0.01) to Dec. 2025 (0.01). It may suggest that Compumedics is progressively becoming more dependent on debt to grow their business.

Compumedics (ASX:CMP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Compumedics LT-Debt-to-Total-Asset Related Terms

Compumedics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Compumedics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compumedics LT-Debt-to-Total-Asset Chart

Compumedics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

0.03

0.02

0.00

Compumedics Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.02	0.01	0.00	0.01

61GF Score

Compumedics Ltd ASX:CMP

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Compumedics LT-Debt-to-Total-Asset Calculation

Compumedics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (A: Jun. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2025 )	/	Total Assets (A: Jun. 2025 )
	=	0.184	/	54.341
	=	0.00

Compumedics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	0.638	/	54.182
	=	0.01

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.01 mean?

Compumedics (ASX:CMP) has a LT-Debt-to-Total-Asset of 0.01 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Compumedics and its competitors.

Is Compumedics' LT-Debt-to-Total-Asset too high?

Compumedics' current LT-Debt-to-Total-Asset is 0.01. Overall, Compumedics has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Compumedics' LT-Debt-to-Total-Asset compare to ABT and SYK?

Compumedics' LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Compumedics and its competitors. Compumedics's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Compumedics stock overvalued right now?

Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.31, compared to a current price of A$0.26 — trading 17.7% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. Compumedics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current LT-Debt-to-Total-Asset is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Compumedics (ASX:CMP) Overvalued in 2026?

Based on GuruFocus' analysis, Compumedics stock appears to be undervalued. The current stock price of A$0.26 is trading 17.7% below its estimated GF Value™ of A$0.31. GuruFocus considers Compumedics to be Modestly Undervalued.

Key valuation signals for ASX:CMP:

LT-Debt-to-Total-Asset: 0.01
GF Value™: A$0.31 vs. price of A$0.26 (17.7% below fair value)
GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Compumedics Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ASX:HMD ASX:COV ASX:CSX ASX:EYE ASX:MX1 ASX:CVB ASX:CBL ASX:AT1 ASX:CQT ASX:OSL ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Address 30-40 Flockhart Street, Abbotsford, Melbourne, VIC, AUS, 3067

Website https://www.compumedics.com.au

Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.

61GF Score

Get the complete analysis for ASX:CMP

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.26

Price

A$0.31

GF Value

View ASX:CMP Analysis

See LT-Debt-to-Total-Asset data for all stocks →